In this episode of Life Science Success, we sit down with Paul Jaminet, Ph.D., founder and CEO of Angiex, Inc., to explore his groundbreaking work in developing Nuclear-Delivered Antibody-Drug Conjugates™ for cancer therapy. Paul shares his unique career journey from astrophysics to biotech, insights into leading innovative projects, and the challenges and triumphs of pushing the boundaries in cancer treatment. Don't miss this inspiring conversation with a visionary leader in the life sciences.

🔗 Learn more about Angiex, Inc.: https://angiex.com/ 📚 Discover Paul's book, "Perfect Health Diet": https://www.amazon.com/Perfect-Health... 🎙️ Subscribe for more insights from top industry leaders!

 

In this episode of Life Science Success, host Don interviews Paul Jaminet, founder and CEO of Angenex. Paul shares his unique journey from astrophysics to life sciences, detailing his groundbreaking work in developing nuclear delivered antibody drug conjugates targeting angiogenic tumor vasculature. Learn about the challenges, motivations, and scientific discoveries driving Angenex's success.   Sponsored by D3 Digital Media Marketing.     00:00 Introduction to Life Science Success Podcast 00:41 Sponsor Message from D3 Digital Media Marketing 01:23 Interview with Paul Jaminet: Founder and CEO of Angenex 01:45 Paul Jaminet's Journey from Astrophysics to Life Sciences 04:35 The Birth of Angenex and Its Groundbreaking Work 06:34 Challenges and Innovations in Developing Antibody Drug Conjugates 13:07 Phase One Clinical Trials and Progress 25:59 Leadership and Strategic Decisions in Biotech 37:10 Inspiration and Motivation Behind the Work 41:10 Concerns and Future Outlook 46:00 Conclusion and Final Thoughts

In this episode of Life Science Success, host Don interviews Artug Akar, Chief Operating Officer at Mercury, about his journey from mechanical engineering in Turkey to leading logistics transformation in the life sciences and healthcare sectors. Artug shares insights on the complexities and challenges of logistics, particularly cold chain management, during the pandemic. They also discuss Mercury's innovative digital transformation initiatives in logistics, such as AI and blockchain. Artug emphasizes the importance of trust, empathy, and leading by example in leadership, along with the benefits of growing and supporting team members. This episode is brought to you by D3 Digital Media Marketing.     00:00 Introduction to Life Science Success Podcast 00:33 Sponsor Message: D3 Digital Media Marketing 01:21 Interview with Artug Akar: Transforming Logistics in Life Sciences 01:53 Artug Akar's Background and Journey 03:30 Impact of the Pandemic on Mercury 06:08 Mercury's Role in Healthcare and Life Sciences 08:58 Challenges and Innovations in Cold Chain Logistics 12:16 Digital Transformation and Future Projects at Mercury 14:58 Leadership and Personal Insights from Artug Akar 25:50 Conclusion and Final Thoughts

Tushar Pandey is a distinguished expert in the Life Sciences industry, currently making significant strides at SimBioSys with his innovative approach to healthcare technology. His contributions have been pivotal in advancing medical solutions and improving patient outcomes.   In this episode of the Life Science Success Podcast, host Don interviews Tushar Pandey, CEO and Co-founder of SymBioSys, an innovative company reshaping precision cancer care. Tushar shares his intriguing journey from Uganda to the United States, his transition from engineering to healthcare, and the personal experiences that sparked his passion for precision medicine. The discussion highlights SymBioSys’ groundbreaking work in creating digital, cost-effective diagnostics to reduce uncertainty in cancer treatment. They explore the importance of addressing diversity in medical models, harnessing the power of AI, and solving challenges in drug development and patient care. Agendas like the company's comprehensive platform for early-stage breast cancer get a deep dive, showcasing how they bridge imaging, genomics, and patient-centered care for improved outcomes. This conversation is a rich mix of personal narrative, professional insights, and forward-thinking solutions in life sciences.     00:00 Introduction to Life Science Success Podcast 00:34 Sponsor Message from D3 Digital Media Marketing 01:25 Guest Introduction: Tushar Pandey 02:27 Tushar's Background and Journey 04:30 Early Career and Transition to Healthcare 06:01 Strata Decision Technology and Cost Optimization 07:57 Personal Impact of Cancer and Shift to Precision Medicine 08:54 Founding Symbiosis and Mission 11:04 Challenges and Innovations in Cancer Treatment 12:21 Symbiosis' Approach to Precision Medicine 14:04 Scientific and Emotional Theses 15:34 Digital Solutions and Global Scale 15:58 Breast Cancer Treatment and FDA Approval 18:05 Supporting Drug Developers and Dosing Regimens 19:30 Digital Orientation and Multi-Omics Data 20:24 Identifying Critical Data in Precision Medicine 20:50 Incorporating Diversity in Medical Models 23:49 Innovative Projects in Digital Health 25:07 The Role of Imaging in Precision Medicine 31:08 Challenges in Life Sciences and Overcoming Them 33:31 Leadership and Inspiration in Precision Medicine 37:28 Concerns and Future Directions in Healthcare 42:02 Conclusion and Final Thoughts  

In this episode of the Life Science Success Podcast we are joined by Stephanie Oestreich, Managing Director of the Myeloma Investment Fund, who has an extensive background in life sciences, leadership, and a unique perspective as a semi-professional violinist.

 

Stephanie shares her extensive background in life sciences and leadership, and discusses her passion for finding cures and treatments for devastating diseases like multiple myeloma. She provides insight into the innovative work of the Myeloma Investment Fund, their mission, and the process of fostering and investing in breakthrough therapies. Stephanie also touches on her teaching role at MIT and her unique perspective as a semi-professional violinist, drawing parallels between her musical and professional experiences.   00:00 Introduction to the Podcast 00:32 Sponsor Message: D3 Digital Media Marketing 01:21 Meet Stephanie Asterik 01:54 Stephanie's Journey in Life Sciences 03:48 The Complexity of Multiple Myeloma 04:51 Investing in Innovation 08:42 The Role of the Myeloma Investment Fund 11:03 Stephanie's Background and Leadership Lessons 15:02 The Art of Playing the Violin 18:33 Leadership Insights from Music 22:07 Final Thoughts and Reflections 27:55 Conclusion and Farewell  

In this episode of Life Science Success, host Don interviews Dr. Sam Clark, founder and CEO of Terran Biosciences. They talk about Dr. Clark's innovative approach to creating new neuropsychiatric therapeutics and how his personal experiences with mental illness inspired him to enter the biotech industry.   The episode also explores various breakthroughs at Terran, including their innovative work with prodrugs, anti-psychotics, and psychedelics, along with their unique, efficient team structure modeled after Silicon Valley tech companies. Additionally, they delve into the inspiration, challenges, and methodologies that drive Terran's mission to provide affordable and modern treatments for patients in need.     00:00 Introduction to Life Science Success Podcast 00:40 Sponsor Message from D3 Digital Media Marketing 01:21 Guest Introduction: Dr. Sam Clark 02:12 Dr. Clark's Journey into Biotech 04:15 Founding Terran Biosciences 07:13 Innovative Projects at Terran 13:00 Psychedelic Compounds and Patient Use 20:00 Overcoming Barriers in Drug Development 23:57 Leadership and Inspiration 31:09 Conclusion and Final Thoughts

In this episode of Life Science Success, host Don interviews Vance Lyon, an accomplished chemist with a four-decade career in the life sciences industry. Vance discusses his educational background, career journey, and key experiences.   The conversation also delves into the vital role of Davos Pharma in providing comprehensive services for biotech companies, including API production, formulation, and IND filings. Vance shares insights on leadership, his inspirations, and concerns, while reflecting on his contributions to significant pharmaceutical projects. Join us for an engaging discussion on life sciences, chemistry, and the intricacies of pharmaceutical development.     00:00 Introduction to Life Science Success Podcast 00:39 Sponsor Message: D3 Digital Media Marketing 01:22 Meet Vance Lyon: A Journey in Chemistry 02:27 Early Life and Education 07:22 Career Beginnings at Parish Chemical 11:08 Transition to Kemmerer Polytech 12:57 Joining Davos and Key Projects 16:06 Services Provided by Davos 27:34 Leadership and Personal Insights 35:52 Conclusion and Farewell

In this episode of the Life Science Success Podcast, host Don Davis, PhD, MBA, interviews Dr. William Chou of Passage Bio. Dr. Chou discusses his transition from a practicing physician to a leader in biotechnology, reflects on the profound patient relationships he misses, and shares insights into Passage Bio's work on gene therapy for neurodegenerative diseases like Frontotemporal Dementia (FTD). They delve into the progress of their Phase 1/2 clinical study, the urgency of developing treatments for genetic mutations, and the potential impact on patients and their families.   Learn about the most recent developments and how Passage Bio is working to give those suffering from these life-threatening conditions hope.   00:00 Welcome and Introduction 00:25 William's Journey into Life Sciences 01:30 The Emotional Impact of Leaving Clinical Practice 02:31 Overview of Passage Bio 02:52 Understanding Frontotemporal Dementia (FTD) 06:38 Current Progress and Future Prospects 10:04 The Urgency and Hope for FTD Treatments 11:37 Goals and Closing Remarks

In this episode of the Life Science Success Podcast, Don Davis PhD, MBA interviews Igor Fisch, founder of NewBiologix. Igor shares his journey from academia to entrepreneurship, highlighting his success with Selexis, a company he sold in 2017 that specialized in monoclonal antibodies. He discusses the challenges of gene therapy, specifically the high costs, and NewBiologix's innovative approach to making gene therapy more affordable. Igor also provides insights into the industry's future, emphasizing the significance of stable production platforms for viral particles.

00:00 Introduction and Welcome

00:15 Igor's Journey into Life Sciences

00:37 The Success of Selexis

00:56 Transition to Gene Therapy

03:32 Challenges in Gene Therapy

03:50 The Importance of Stable Platforms

05:11 The Role of Biotech Startups

05:57 Balancing Science and Business

06:51 Networking at BIO Conference

08:14 Future Vision for New Biologics

09:21 Conclusion and Farewell

In this episode of the Life Science Success Podcast, Dean Petkanas, co-founder of Kannalife Sciences, is interviewed at the Bio International Convention in San Diego. Dean shares his journey from investment banking in the 80s to founding Kannalife Sciences in 2009. He discusses the company's focus on developing cannabinoid-based drugs, specifically targeting chemotherapy-induced peripheral neuropathy. The conversation covers the challenges and opportunities in cannabinoid drug development, the importance of targeting specific types of pain, and the current state and future prospects of Kannalife Sciences. Dean also highlights the significance of partnering and collaboration in advancing novel therapeutics.       00:00 Welcome to the Life Science Success Podcast 00:20 Dean's Journey into Life Sciences 01:04 The Evolution of Kannalife Sciences 02:18 Challenges and Opportunities in Cannabinoid-Based Drugs 03:06 Understanding Pain and Neuropathy 06:08 Investment Insights and Market Trends 07:40 Kannalife Sciences's Current Focus and Future Prospects 10:02 The Importance of Partnering at Bio 11:02 Closing Remarks and Future Meetings  

In this episode of the Life Science Success Podcast, host Don interviews Sean Rothwell, CEO of Evoke Nano, about the company's groundbreaking work in developing EBQ218, a revolutionary nanoparticle-based pulmonary therapeutic. They discuss the efficacy of EBQ218 in treating cystic fibrosis and its potential as a broad-spectrum antibiotic against drug-resistant superbugs. Sean shares insights into the company's journey, their upcoming clinical trials, and the broader impact of their work on patient outcomes in the healthcare landscape. Tune in to learn how Evoke Bio is poised to make a significant difference in combating infectious diseases and improving lives.     00:00 Welcome and Introduction 00:09 First Impressions of BIO Conference 00:37 Sean's Background and Journey into Life Sciences 01:42 The Science Behind Evoke Nano 02:28 EBQ218: A Revolutionary Pulmonary Therapeutic 04:16 Challenges and Future Pathways 05:24 Investment and Partnership Opportunities 06:42 Broader Applications and Future Vision 08:16 Addressing Drug Resistance and Regulatory Pathways 18:48 Conclusion and Final Thoughts

This is the second part of the interview where, with Maruiano, we will discuss more of the technology and development for Elem Biotech.  

 

In this episode of the Life Science Success Podcast, Don Davis discusses the BIO conference and the future of biomedical research with Mauriano Vázquez. They delve into the significance of networking events, the evolution of computing capabilities, advanced simulation codes, and the potential applications of AI and quantum computing in life sciences. Mauriano shares his unique journey from Argentina to becoming a physicist specializing in computational mechanics, and how his work in cardiac electrophysiology can significantly impact patient care. The conversation wraps up with insights into the future use of virtual and augmented reality in medical applications.     00:00 Introduction and Conference Impressions 02:37 Mariano's Background and Journey into Life Sciences 06:22 Applications of Simulation Technology 10:48 Evolution of Computing Capabilities 13:37 Future of AI and Quantum Computing 14:41 Virtual Reality in Medical Applications 19:40 Conclusion and Final Thoughts

There are two parts of this interview, in the first session, I dive into Elem and what the company is doing with Christopher Morton.  

 

In this exciting episode of Life Science Discussed Podcast, host Don Davis welcomes Christopher Morton, CEO of Elem Biotech, to talk about the groundbreaking work of virtual human twins in drug and medical device testing. Morton, an aeronautical engineer turned biotech innovator, discusses Elem's platform that allows pharmaceutical companies, medtechs, and CROs to test new therapeutics using virtual human models instead of animal models. They delve into how this approach, distinct from AI-based methods, focuses on mechanistic modeling using MRIs and CT scans to replicate human physiological functions. Morton explains how Elem Biotech's solutions help in precision medicine, clinical trial design, and reducing animal trials, supported by supercomputing power and cloud technology. Tune in to discover how virtual human models are poised to transform life sciences and medical testing.   00:00 Introduction and Welcome 00:43 Christopher Morton's Background 01:57 Introduction to Elem Biotech 02:45 Mechanistic Approach vs. AI Models 03:47 Precision Medicine and Virtual Human Twins 08:58 Supercomputing and Technological Infrastructure 13:07 Applications in Pharma and Medical Devices 21:07 Challenges and Future Directions 25:59 Conclusion and Final Thoughts

Scaling Innovations in Life Sciences: An Interview with Tim Glennon | Life Science Success In this episode of Life Science Success, host Don interviews Tim Glennon, the principal owner of Illumination Strategy Group. With more than 26 years of experience in the pharmaceutical industry, Tim shares his journey, starting from his early career at Bayer to leadership roles at Teva and other companies.   The discussion covers the importance of strategic commercial planning for pre-IPO biopharma companies, the role of commercial involvement from the pre-IND stage, and how smaller companies can effectively scale their innovations. Tim also touches on his motivations for founding Illumination Strategy Group, the impactful trends in the pharmaceutical industry, and the significance of AI in drug development. Additionally, leadership advice, ongoing learning, and the excitement of new challenges are explored in this insightful conversation.     00:00 Introduction to Life Science Success Podcast 00:42 Sponsor Message from D3 Digital Media Marketing 01:24 Guest Introduction: Tim Glennon 01:55 Tim Glennon's Career Journey 04:08 Insights on Working in Big Pharma vs. Small Pharma 09:07 Founding Illumination Strategy Group 14:34 The Importance of Commercial Strategy 16:55 Challenges and Opportunities in Biopharma 35:42 Leadership and Personal Growth 43:00 Conclusion and Final Thoughts

In this episode of the Lifescience Success Podcast, host Don Davis interviews James Hackworth, who shares insights about his background in physics and his journey into the life science industry. James discusses his experiences from McKinsey up to his current role at Tris Pharma, focusing on their innovative drug development and formulation technologies. He dives into the company's advancements in ADHD medications and an exciting new pain management drugs. Additionally, the conversation highlights the importance of partnerships, technology in drug development, and future industry trends. James provides a fascinating glimpse into the complexities and future of pharmaceuticals.

00:00 Welcome and Introduction
00:08 Impressions of the Bio Conference
00:42 James' Background and Journey into Pharma
03:17 Formation and Growth of Park Therapeutics
04:20 Overview of Tris Pharma
04:41 Tris Pharma's Focus and Innovations
08:00 Challenges and Opportunities in Partnering
10:58 Future of Tris Pharma and the Industry
15:41 In-depth Look at Drugs that are progressing
19:21 Conclusion and Final Thoughts

In this episode of the Life Science Success Podcast, Don interviews Himanshu Gadgil  from Enzine during Bio International. Himanshu explains Enzine’s dual focus on developing biosimilars and their role as a CDMO with a game-changing platform, Enzine X. They discuss how Enzine's continuous manufacturing technology significantly cuts costs and speeds up market access for clients. Himanshu also talks about Enzine’s global presence, clientele, and their future plans for expansion in the U.S. and India. Tune in to learn about the innovative approaches Enzine is bringing to the biotech industry.   00:00 Welcome and Introduction 00:07 Overview of Enzine Biotech 00:26 Enzine's Unique Manufacturing Platform 01:08 Clientele and Market Reach 01:41 Timelines and Efficiency 02:08 Future of Continuous Manufacturing 04:22 Geographical Expansion and Workforce 05:02 Enzine's Differentiators 06:10 Conclusion and Final Thoughts  

Join us on the Life Science Success Podcast as we delve into the fascinating journey of Andy Mehrotra, a pharmacist turned entrepreneur, who pioneered Unipr, an AI and machine learning platform aimed at addressing inefficiencies in drug development. Learn about his transition from sales and marketing to leading an innovative company, the significance of integrating and unifying data, and how Unipr is reshaping the pharmaceutical industry. Discover how Unipr is not just a solution for the life sciences but a model for other complex industries. Listen in for insights on the future of collaborative technology and its potential to accelerate health innovations.   00:00 Introduction and Guest Welcome 00:06 Guest Background and Career Journey 01:19 Transition to Leadership 02:29 Pharmaceutical Industry Insights 06:00 Introduction to Unipr 06:08 Uniper's Technology and Solutions 08:56 Client Use Cases and Success Stories 12:37 Integration vs. Unification 17:23 Conference Goals and Future Vision 21:41 Conclusion and Final Thoughts  

Welcome to the Life Science Success Podcast! In this episode, host Don interviews Catherine from Jellox Biotech at Bio Interntional June of 2024. Catherine shares insights into her journey from financial engineering to the life sciences field, her experience in investment banking, and her current role in business development at Jellox Biotech. She discusses Jellox Biotech's groundbreaking 3D imaging technology for digital pathology, its benefits for early cancer diagnosis, and the company's expansion plans. Catherine also sheds light on the challenges and hopes for the future, especially regarding raising venture capital and global outreach.     00:00 Introduction and Guest Welcome 00:07 Catherine's Background and Career Journey 00:43 Introduction to Jellox Biotech 01:11 Innovations in 3D Imaging and Digital Pathology 02:22 Product Development and Market Expansion 03:56 Challenges and Goals at Bio Conference 08:06 Global Expansion Plans 09:37 Future Aspirations and Technological Impact 15:39 Conclusion and Farewell

In this episode of the Life Science Success podcast, we have Dr. David E. Martin, the President and CEO of TrippBio, Inc., a distinguished translational scientist with over 30 years of experience in drug development. Dr. Martin has led numerous groundbreaking projects and is here to share his insights on the future of therapeutic advancements.

 

🚀 Book a FREE Digital Marketing strategy Session 👉 https://link.cxnector.com/widget/book...

 

• Introduction of Dr. David E. Martin: Dr. David E. Martin, with over 30 years in drug development, joins Don on the "Life Science Success" podcast to discuss his career and insights into therapeutic advancements.

• Dr. Martin's Background: Dr. Martin, trained as a pharmacist during the AIDS epidemic, developed a passion for infectious diseases and clinical research, which led him into life sciences. His career is marked by his role as a translational scientist focusing on groundbreaking projects.

• Professional Achievements: He highlights his work with HIV RNA as a surrogate marker in drug development, detailing his involvement in pioneering studies that validated PCR technology in clinical trials. This work significantly contributed to how drug efficacy is evaluated, particularly concerning HIV treatments.

• Role at TrippBio: As the CEO of TrippBio, Dr. Martin discusses the company's focus on developing drugs targeting host factors rather than the pathogens themselves, reducing the likelihood of resistance. TrippBio is exploring treatments for major respiratory viruses using this novel approach.

• Vision and Challenges: Dr. Martin shares his vision for TrippBio to develop a universal treatment for major respiratory infections and discusses the challenges small biotechs face, especially in securing funding and managing innovative research within tight budgets.

In this episode of Life Science Success, host Don Davis PhD, MBA, a digital marketer in life sciences, interviews Sabrina Johnson, CEO, and founder of DARE Bioscience. With a passion for advancing women's healthcare, Sabrina shares her career path from biochemical engineering to founding DARE Bioscience. She discusses the inception of the company, its innovative pipeline, including non-hormonal contraceptives and treatments for female arousal disorder, and the unique challenges they faced, like funding and public awareness. Sabrina emphasizes the importance of addressing unmet needs in women’s health, the strategic decisions behind their reverse merger, and her optimistic vision for the future of women's health treatments.

 

Key Takeaways

1. Purpose-Driven Innovation: Daré Bioscience was founded to address significant gaps in women's healthcare, driven by Sabrina Johnson's commitment to making a difference in areas with unmet needs.
2. Strategic Funding: Opting for a public company model allowed Daré Bioscience to secure necessary funding for its extensive product pipeline.
3. Collaborative Development: Partnering with established companies like Bayer helps in the commercialization and broader reach of innovative products.
4. Focus on Unmet Needs: The company's approach starts with identifying specific unmet needs in women's health, ensuring their products address significant issues.
5. Leadership and Authenticity: Sabrina Johnson highlights the importance of authentic leadership, problem-solving, and not shying away from challenges to drive innovation and success in healthcare.

In this episode of the Life Science Success Podcast, host Don Davis interviews Christian Engstrom, CEO of Bullpen, an elite club focused on fostering collaborative success in the life sciences industry. They discuss Christian's background, his motivation for creating Bullpen, the club's mission to help entrepreneurs and investors connect and support each other, and the various success stories stemming from Bullpen's initiatives. They also delve into upcoming events at the BIO International Convention and the club's future direction. Christian emphasizes the power of authentic networking and resource sharing among life sciences professionals.

 

Key Takeaways:

1. Collaborative Environment: Bullpen Ventures fosters a collaborative environment where members can network and support each other, addressing gaps in the life sciences sector.

2. Event Organization: Bullpen organizes unique, engaging events at major conferences to facilitate networking and partnerships among life science professionals.

3. Philosophical Approach: The club operates on mutual support, humility, and leveraging each member's strengths to create a supportive and effective community.

4. Non-Profit Focus: Bullpen emphasizes non-profit collaboration and relies on sponsor partners to cover costs, ensuring that resources are directed towards helping entrepreneurs and small businesses.

5. Future Vision: Bullpen aims to be a hub for DEI initiatives and a power center for collaboration, with a focus on aligning with partners who share their values and contribute to the community's success.

 

 

In this episode, we sit down with Aron Knickerbocker, President and CEO of Aulos Bioscience. Aron shares his extensive experience in the Life Sciences industry, highlighting his pivotal roles at RayzeBio, Five Prime Therapeutics, and Genentech. He discusses Aulos’ innovative approaches to cancer treatment, particularly in radiopharmaceuticals and targeted therapies. Aron also reflects on the key leadership advice that has shaped his career and shares his insights on the future of oncology. Tune in to learn about the groundbreaking work at Aulos and Aron’s vision for advancing cancer treatment.

 

 

• Personal Motivation: Aron’s dedication to cancer treatment is deeply personal, influenced by his mother’s death from cancer.
• Innovative Approaches: Aulos Biosciences uses immune system engagement instead of traditional radiotherapy, showing promise in early trials.
• Diverse Experience: Aron’s career spans research, business development, and leadership roles, providing a comprehensive understanding of the biotech industry.
• Leadership Values: Effective decision-making, scientific rigor, and a strong team are central to Aron’s leadership style.
• Future Vision: Aron envisions AU-007 making a significant impact on cancer treatment, with aspirations of achieving groundbreaking results in clinical trials.

https://www.lifesciencesuccess.com/pauledwards/

Paul Edwards is the President and CEO of DoseMeRx. He has been a Senior Executive with Merck and GSK, and start-ups including ILUM Health Solutions, Infectious Disease Connect, and TrackMy Solutions. He has an extensive history in infectious disease, antimicrobial stewardship, and precision medicine.

 

• Guest Introduction: Paul Edwards, the President and CEO of DoseMeRx, shares his extensive background in the pharmaceutical industry, including roles at Merck, GSK, and various startups, focusing on antibiotics and infectious diseases.

• Pharmaceutical Journey: Paul discusses his career progression from selling macrolides to leading infectious disease units and moving to the U.S. to transform commercial models at Merck, emphasizing the importance of real-world data over clinical trial data.

• DoseMeRx Focus: DoseMeRx specializes in precise dosing for critically ill patients using therapeutic drug monitoring, particularly for injectable antibiotics, aiming to provide accurate dosing information through web-based and integrated models within hospital systems.

• Challenges and Future of Medicine: Paul highlights the importance of antimicrobial stewardship, pharmacogenomics, and personalized medicine in improving patient care and expresses concerns about the current insurance and payment systems based on actuarial science.

In this episode of the Life Science Success Podcast, I am joined by Dr. Rafael G.
Amado, an esteemed leader in oncology research and development, currently serving as
the President and Head of Global Oncology at Zai Lab. With a distinguished career
spanning multiple leading biotech firms, Dr. Amado brings a wealth of experience in
gene-engineered cell therapies and innovative cancer treatments.

 

• Professional Background: Dr. Rafael G. Amado is currently the president and head of global oncology at Zai Lab. He has a rich background in medicine, starting with his education in Spain, followed by a move to the U.S. where he specialized in Internal Medicine and later Hematology Oncology at the University of California, Los Angeles.

• Passion for Oncology: Dr. Amado's interest in oncology stems from its complex nature and the multifaceted approach it requires, combining diagnostics, therapeutics, and a detective-like inquiry into patient cases. His career shift towards oncology was influenced by its holistic approach to patient care and his personal drive to solve complex medical puzzles.

• Research and Development Focus: At Zai Lab, Dr. Amado oversees oncology research and development, focusing on gene-engineered cell therapies among other innovative treatments. He has been involved in significant breakthroughs, such as determining drug inefficacies in patients with certain genetic mutations, which has influenced global regulatory changes in cancer treatment.

• Corporate and Global Strategy: Under Dr. Amado’s leadership, Zai Lab has approved six drugs in China, with a strong emphasis on addressing grievous illnesses through open innovation. He is instrumental in expanding the company's global reach, aiming to impact a broad patient base internationally by aligning clinical trials and regulatory strategies across diverse geographic locations.

• Vision and Future Goals: Dr. Amado is committed to advancing drug development that significantly outweighs potential risks with therapeutic benefits. He is driven by a mission to impact oncology treatment on a global scale, with ambitious goals to reach approximately a million patients by 2030 through continuous innovation and strategic drug development.

In this episode of Life Science Success, host Don Davis PhD, MBA interviews Alba Panatti Johnson, the Assistant Director of Economic Development for Sugar Land, Texas. Alba shares her journey from finance to economic development and discusses her role in fostering business retention, expansion, and attraction within Sugar Land. The conversation delves into the city's strategic initiatives, including the development of a life science campus and innovative projects like a new power plant. Alba also highlights the importance of customer service, community engagement, and future visions for the life sciences industry in the region. Additionally, the episode includes a sponsorship message from D3 Digital Media Marketing.   00:00 Introduction to Life Science Success Podcast 00:43 Sponsor Message: D3 Digital Media Marketing 01:24 Meet Alba Panatti Johnson 01:54 Alba's Journey in Economic Development 04:30 Geographical Insights: Sugarland, Texas 05:18 International Business and Economic Development 13:45 Life Sciences in Sugarland 18:10 Supporting and Nurturing Local Businesses 20:46 Advantages of Sugarland for Life Sciences 27:18 Innovative Initiatives and Future Vision 35:27 Leadership and Personal Insights 42:32 Conclusion and Final Thoughts

This week on the Life Science Success Podcast my guest is Dan Lunz. Dan Lunz is the CEO and Co-founder of Previse, a pioneering company based in Baltimore, Maryland, that specializes in offering tests for the prediction and earlier detection of upper-GI cancers.

 

• Background of Dan Lunz: Dan Lunz, CEO and co-founder of Previse, shares his journey from growing up in Baltimore, serving in the Marine Corps, experiencing healthcare firsthand as a patient in the VA system, to studying at Johns Hopkins and working in clinical research. His career path was significantly influenced by his desire to serve others, leading him to the life sciences sector.

• Formation of Previse: Lunz's collaboration with Dr. Steven Meltzer, a professor at Johns Hopkins, sparked the founding of Previse. They focused on developing diagnostic tools for early detection of upper GI cancers based on Meltzer's research on biomarkers. Their shared mission was to improve patient outcomes through innovative medical technologies.

• Previse's Diagnostic Innovations: Previse specializes in detecting and predicting upper gastrointestinal (GI) cancers. The company offers a commercial test called ESO Predict, which assesses the risk of esophageal cancer in patients with conditions like Barrett's esophagus, helping physicians strategize patient management and surveillance intervals.

• Challenges and Leadership Insights: Throughout the interview, Lunz discusses the entrepreneurial challenges of securing funding and navigating regulatory landscapes. He emphasizes the importance of perseverance and humility in leadership, learning from rejections, and the critical role of assembling a talented team to overcome complex challenges.

• Future Goals and Impact: Looking forward, Previse aims to expand access to its existing diagnostics across the U.S. and continue developing non-endoscopic tools and medical devices to enhance GI cancer detection. Lunz is driven by the potential impact of their technology in preventing cancer and improving patient care, underscoring his dedication to service and innovation in life sciences.

In this episode of the Life Science Success Podcast our guest is Leonard Mazur, CEO and Co-Founder of Citius Pharmaceuticals. With over 50 years of experience in the biopharma industry, Leonard has been at the forefront of developing groundbreaking therapies for patients with unmet medical needs.

 

• Background and Entry into Biopharmaceuticals: Leonard Mazur, CEO and co-founder of Citius Pharmaceuticals, began his career through an unexpected newspaper ad, leading him to pharmaceutical sales. His liberal arts background as a psychology major did not initially suggest a career in biopharma, highlighting the unpredictability of career paths.

• Early Career Development: Mazur's rapid career advancement occurred within Cooper Laboratories, an entrepreneurial company where he transitioned from sales to marketing and strategic planning. This period involved substantial growth through acquisitions, providing him with a broad range of experiences in the pharmaceutical sector.

• Entrepreneurial Ventures: Throughout his career, Leonard Mazur has initiated multiple entrepreneurial efforts, ultimately leading to the founding of Citius Pharmaceuticals. His story is marked by significant risk-taking, including personal financial stakes in business initiatives, reflecting his deep commitment to his entrepreneurial pursuits.

• Focus of Citius Pharmaceuticals: Citius Pharmaceuticals, which Mazur co-founded, is dedicated to developing innovative treatments for critical care. A key product from Citius is an antibiotic lock solution for treating infections in central venous catheters, illustrating the company's commitment to addressing complex medical needs.

• Views on Industry and Innovation: Mazur discusses the critical role of the biopharmaceutical industry in global drug development, emphasizing the potential risks to innovation from policy changes such as the implementation of socialized medicine. His insights reflect on the industry's dynamics and the importance of sustaining an environment conducive to pharmaceutical innovation.

In this episode of Life Science Success, we sit down with Marc, an entrepreneur, certified coach, and a beacon of leadership in the life sciences and business coaching sectors. Marc shares his journey from the entrepreneurial services group at EY to founding and leading companies in the life sciences field, and how he leverages his vast experience to mentor and inspire others towards professional excellence and personal growth. Tune in for a deep dive into the intersection of business acumen and scientific innovation, and discover Marc's unique approach to fostering success in the competitive world of life sciences.

 

• Marc Cote's background includes a transition from being a CPA at Ernst & Young to becoming an entrepreneur and certified coach, focusing on leadership within the life sciences. He credits his father, a second-generation business owner, for influencing his career path and emphasizing the importance of a strong business foundation.
• During his career, Cote identified a gap in leadership and soft skills training among highly technically trained professionals in the life sciences. He aims to help these individuals realize their potential not only as scientists but also as visionary leaders and effective managers.
• Cote discusses his journey from consulting at Ernst & Young to launching his own companies that supported biotech and small pharmaceutical companies. He emphasizes the value of leadership coaching to enhance emotional intelligence (EQ), crucial for effective leadership.
• The podcast conversation covers Cote's approach to coaching, focusing on understanding and leveraging one's strengths and appreciating different leadership styles. He highlights the importance of continuous personal development and adaptability in achieving career advancement within the life sciences.

In this episode of Life Science Success, my guest is Darwin Shurig, founder and CEO of Shurig Solutions.  Darwin brings strategic value to medical device, life science, and pharma companies. Darwin is responsible for most, if not all, business processes, including project management, recruitment, sales, operations, quality, and regulatory affairs, to mention a few.

 

• Guest Introduction: Darwin Shurig, the guest, is introduced as the founder and president of a company involved in the recruitment industry, particularly within the life sciences sector. Darwin shares his journey of starting the business, highlighting his prior experience in clinical respiratory therapy and his transition to entrepreneurship nearly nine years ago.

• Business Challenges and Insights: Darwin discusses the challenges he faced as a newcomer to the business and recruitment industries. He emphasizes the importance of resilience, learning from failures, and the critical role of understanding market needs and analytics to sustain a business in a competitive environment.

• Recruitment Philosophy and Strategies: Throughout the interview, Darwin explains his approach to recruitment, focusing on the importance of specialization, understanding client needs, and delivering value without having to return fees. He stresses a high client acceptance rate and successful placement track record as indicators of his company's effectiveness.

• Industry Perspective and Future Outlook: Closing the conversation, Darwin reflects on the broader industry trends, including the impact of technology like AI on recruitment and other business processes. He is optimistic about the potential of new technologies to enhance business efficiency and expresses curiosity about future developments in life sciences and AI.

In this episode of Life Science Success, host Don Davis has a conversation with Dr. Mohit Jain, a physician scientist with extensive experience in physiology, biomedicine, and mass spectrometry. Dr. Jain shares his unique journey from clinical training to leading breakthroughs in mass spectrometry and computational biology.

He discusses the inception of Sapient Bio, a company that leverages mass spectrometry to unlock new horizons in drug discovery and patient diagnosis by analyzing thousands of molecules in the human body. They explore the future of medicine, emphasizing personalized therapy and the potential to diagnose diseases like diabetes and Alzheimer's years in advance.

Dr. Jain also sheds light on the challenges and opportunities in biotech, the impact of computational biology, and the pivotal role of Sapient Bio in pioneering the field of drug discovery. The conversation concludes with Dr. Jain's reflections on leadership, inspiration, concerns, and what excites him about his work, offering deep insights into the promising future of life sciences.

 

Key Highlights: 

01:23 Introducing Dr. Mohit Jain: A Multifaceted Scientist 02:04 The Journey to Sapient Bio: Unraveling Dr. Jain's Career Path 03:39 The Evolution of Mass Spectrometry and Its Impact on Health 06:45 Sapient Bio: Democratizing Access to Advanced Technologies 13:33 Challenges and Opportunities in Leading a Biotech Company 16:54 The Future of Drug Discovery and Personalized Medicine 23:47 Sapient Bio's Differentiation and Future Prospects 29:24 Leadership Insights and Personal Reflections from Dr. Jain    

Jennifer Hawks Bland is a distinguished leader in the life sciences sector, serving as the Chief Executive Officer of NewYorkBIO, an organization at the forefront of advancing New York's life sciences ecosystem. With a rich background spanning legal practice, government affairs, and executive leadership in companies like Merck and GlaxoSmithKline, she brings a wealth of experience and insight to her role in fostering innovation and growth within the industry.

 

• Jennifer Hawks Bland, CEO of New York Bio, discussed her unique path into life sciences, transitioning from a legal background where she initially engaged with the pharmaceutical industry through mass tort defense litigation, to advocacy and lobbying roles, eventually leading her to her current position.
• She detailed the mission and operations of New York Bio, highlighting its role in advancing New York’s life sciences ecosystem by collaborating with early-stage companies, academic medical centers, and leveraging the state’s rich resources in life sciences for regional and statewide economic development.
• Hawks Bland emphasized the importance of storytelling in advocacy, drawing on her legal and lobbying background to influence policy and support the life sciences industry, both at the state and federal levels, and how this skill has been crucial in her roles leading up to and including her leadership at New York Bio.
• The conversation also covered the challenges and opportunities facing the life sciences sector, particularly in New York, from fostering startup growth to navigating policy and funding landscapes. She stressed the significance of collaboration across various stakeholders, including government, academia, and the private sector, to drive innovation and support the ecosystem.
• Hawks Bland shared her excitement for the future of life sciences, reflecting on the potential for breakthroughs in health and medicine, and the critical role of advocacy and strategic partnerships in overcoming challenges and capitalizing on opportunities within the industry.

In this episode of Life Science Success, we're thrilled to welcome Britney Winterberger, the Senior Director of North America Project Management and Clinical Operations at Tigermed. Britney brings a wealth of experience in clinical trials across various therapeutic areas and a deep personal commitment to advancing patient treatments, particularly in the fight against cancer.

 

• Britney Winterberger is the Senior Director of North America Project Management and Clinical Operations at Tigermed, with a rich career history in life sciences, inspired by a personal loss to leukemia. She initially aspired to be a pediatric oncologist but shifted towards clinical research to contribute to cancer treatment advancements.
• Winterberger, who was born and raised in Cincinnati, Ohio, has a Marquette University undergraduate degree in biological sciences as well as study abroad experiences. She is also a family person, emphasizing the importance of travel, outdoor activities, and being sports enthusiasts with her husband and two children.
• Her journey into the field of life sciences was somewhat unintentional, transitioning from a goal in pediatric oncology to clinical research due to the emotional challenges of the former. She transitioned because of a special opportunity through a family connection, which led her to a career in clinical research organizations (CROs).
• Throughout her career, pivotal moments included receiving a 'B' on a performance review, which was a significant learning experience for her, highlighting the importance of adaptability, innovation, and the need to work in a more agile and innovative environment. Joining Tigermed represented a culminating point where she found a space to innovate and drive meaningful change in the clinical research landscape.
• Winterberger discusses the evolution of clinical trials, emphasizing the shift towards patient-centric approaches, the integration of digital health technologies, and the push for decentralized clinical trials to improve patient access and compliance. She also highlights Tigermed's role in advancing clinical research through innovative trial designs and efficient patient recruitment strategies, underlining her commitment to making a difference in cancer treatment and patient care.

In this episode of Life Science Success my guest is Dr Dr. Rahul Kakkar we will dive into the life and innovations of his tremendous career. From founding groundbreaking biotech companies to his vital role at Tome Biosciences and balancing life as a practicing physician, Rahul's journey is nothing short of inspirational. Discover the cutting-edge of genomic medicine and get a peek into the mind of a true life sciences pioneer.

 

• Dr. Rahul Kakkar's Journey: Dr. Kakkar, CEO of Tome Biosciences and a distinguished biotech executive and physician scientist, shares his journey from training in the Harvard Hospital System to his disillusionment with academia's limitations on drug development. This frustration led him towards a career in biotech, underscored by his entrepreneurial spirit and the significant influence of mentors who supported him at pivotal moments.

• Entrepreneurial Shift and Tome Biosciences: His experiences, particularly at AstraZeneca, highlighted the challenges of navigating entrenched corporate cultures, sparking his entrepreneurial journey. This journey includes the founding of Corvidia Therapeutics and ultimately leading to his current role at Tome Biosciences, where he emphasizes a flat, open company culture focused on innovative drug development.

• Balancing Medicine and Leadership: Kakkar balances his roles as a physician and a biotech leader, finding real-world clinical experiences vital for grounding his work in biotech. He maintains an active part in patient care, which he finds complements his leadership in biotech, keeping his work relevant and impactful.

• Advancements in Biotech and Tome's Focus: Kakkar discusses the evolution of biotechnology, from monoclonal antibodies and nucleotide-based therapeutics to the future of DNA editing. At Tome Biosciences, the focus is on programmable genomic integration, aiming to create differentiated, impactful drugs. This approach underscores the importance of technology in developing meaningful new therapies.

• Leadership Philosophy and Inspiration: Sharing insights on leadership, Dr. Kakkar emphasizes the importance of resilience, adaptability, and making the best of situations. He finds inspiration in the human spirit's perseverance, whether in family, healthcare, or scientific discovery, driving him to overcome challenges in healthcare and biotech innovation.

This week on Life Science Success, we are thrilled to welcome back Elizabeth Smalley as our guest. Elizabeth is the VP, Product Management, Data & Analytics at ArisGlobal, where she plays a pivotal role in steering the company’s strategic initiatives in the realms of artificial intelligence and machine learning within the life sciences sector. With an impressive background that bridges technology and life sciences, Elizabeth has been instrumental in the formation and launch of the GenAI Council, an innovative effort aimed at harnessing generative AI to revolutionize research and development in life sciences.

• Introduction of Guests and Focus: Don, a consultant in life sciences, introduces Elizabeth Smalley, VP of Product Management, Data, and Analytics at ArisGlobal. The discussion emphasizes the transformative power of generative AI (GenAI) in the life sciences sector, with a particular focus on Elizabeth's leadership in strategic AI initiatives at ArisGlobal.

• Elizabeth Smalley's Background and Journey: Elizabeth recounts her diverse experience in product management across e-commerce, manufacturing, and healthtech. Her story highlights the central role of AI in her career, including significant achievements in developing AI-driven clinical solutions at Teladoc Health and her progression to leading ArisGlobal's data, analytics, and AI strategies.

• ArisGlobal's Innovations and Role: The conversation explores ArisGlobal's impact on life sciences, especially its innovative use of AI in pharmacovigilance and regulatory processes. Elizabeth points out ArisGlobal's pioneering introduction of AI into case processing workflows and its leadership in adopting generative AI, aiming to enhance efficiency and patient safety in the sector.

• Generative AI: Challenges and Opportunities: Elizabeth discusses the economic potential of generative AI in life sciences, acknowledging regulatory challenges and the necessity of industry-wide collaboration to navigate these. She emphasizes the importance of creating a responsible AI adoption playbook, addressing transparency, and fostering innovation within a regulatory framework.

• Vision for the Future: The interview concludes with a forward-looking view on how generative AI could revolutionize patient care, streamline drug development, and optimize regulatory compliance. Elizabeth advocates for a collaborative approach to leverage AI responsibly, aiming to improve health outcomes, enhance operational efficiencies, and ensure patient safety in the evolving landscape of life sciences.

 

This week on the Life Science Success Podcast, my guest is Dr. Tiago Reis Marques Dr. Marques is a psychiatrist and currently the Chief Executive Officer of Pas i thea Therapeutics. Pasithea is developing new molecular entities for the treatment of CNS disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome.

 

On this episode of Life Science Success, Don Davis interviews Dr. Tiago Reis Marques, the CEO of PACEA Therapeutics. They discuss Dr. Marques's journey in psychiatry, the company's focus on CNS disorders, their pipeline of drugs targeting neurological conditions like schizophrenia and ALS, and the impact of their research on rare disorders like neurofibromatosis type one. The conversation also touches on leadership advice, inspiration, concerns about global issues, and what excites them.

• Dr. Tiago Reis Marques, a psychiatrist, is the CEO of Pasithea Therapeutics, a company focused on central nervous system (CNS) disorders. His background in medical research and his transition from academia to biotech were driven by a desire to apply his knowledge to develop treatments that benefit patients.
• Pasithea Therapeutics, co-founded with Professor Steinman from Stanford, aims to create innovative therapies for unmet needs in CNS disorders. The company's approach balances new drugs targeting novel mechanisms of action with known drugs repurposed for new applications.
• One of the company's focuses is on neurofibromatosis type one, a disorder affecting around 100,000 patients in the US, highlighting the company's commitment to tackling rare and challenging diseases with significant unmet needs.
• Marques emphasizes the importance of precision psychiatry and targeting specific subtypes of disorders, drawing parallels to how cancer treatments have evolved to focus on specific biomarkers and subtypes, reflecting a broader trend towards personalized medicine.
• His experiences and work in brain imaging, specifically with positron emission tomography (PET) and psychopharmacology, underscore his multidisciplinary approach to understanding and treating CNS disorders, leveraging his academic background to inform his leadership and strategic direction at Pasithea Therapeutics.

In this episode of Lifescience Success, host Don Davis interviews Bill Bullock, a key member of the senior executive team at NC Biotech. Bullock shares his extensive experience in life science economic development, biotechnology consulting, and research. He discusses the incredible growth of North Carolina's life sciences ecosystem, particularly in biomanufacturing, and the unparalleled collaboration among educational institutions, community colleges, and industry.    They explore major recent partnerships and initiatives to enhance workforce development, attract investment, and bolster North Carolina's position as a global life sciences leader. Reflecting on the ambitious history and visionary leadership behind NC Biotech, Bullock emphasizes the ongoing challenge of preparing for the future by continuously innovating and expanding infrastructure to maintain the state's competitive edge.     00:00 Introduction to Lifescience Success Podcast 00:42 Sponsor Message from D3 Digital Media Marketing 01:23 Introducing Bill Bullock 02:33 Bill Bullock's Career Journey 08:56 The Role and Mission of NC Biotech 18:22 Innovative Projects and Initiatives at NC Biotech 25:52 Business Climate in North Carolina 27:13 Impact of COVID-19 on Manufacturing 29:26 North Carolina's Biotech Success 30:23 Founding and Vision of the Biotech Center 35:14 Future of Life Sciences in North Carolina 39:53 Leadership and Personal Insights 47:41 Conclusion and Final Thoughts

In the interview, Don Davis PhD, MBA talks to Toban Zolman about his company, Kivo. Zolman takes us through his impressive journey of over 20 years in life sciences and the transformation he has witnessed in the industry. He further details the services of Kivo, stating that the company helps businesses involved in life sciences, specifically those developing clinical trials for pharmaceutical, medical device, and biotech companies, to streamline and optimize their processes. 

He specifically speaks about the significant shift in the industry from large pharmaceutical companies running drug trials to now being dominated by smaller companies without a product in the market yet. Regarding emerging trends, Zolman anticipates artificial intelligence will have a transformational impact on the industry. He also highlights the importance of knowing when to say "no" and making definitive decisions based on customer's needs, aligning company focus to customer growth, and maintaining transparency in their operations.

 

5 Key Points: 

• Toban Zolman is the CEO of Kivo, with over 20 years of leadership experience in developing, deploying, and validating computerized systems for clinical trials.
• Zolman's career began in the early 2000s at an electronic submission company, pioneering the transition from paper to electronic submissions for pharmaceutical companies globally, impacting 47 out of the top 50 Pharma companies in 16 countries.
• At Kivo, Zolman leverages his extensive background to innovate in life sciences by integrating technology and regulatory best practices to support emerging companies in developing and marketing new drugs efficiently.
• Kivo stands out in the life sciences space by blending deep clinical and regulatory experience with enterprise SaaS expertise, offering a unique approach to accelerating drug development and approval processes.
• Zolman emphasizes the importance of adaptability, saying no to maintain focus, and the potential transformative impact of AI on drug development, viewing it as both an intimidating and exciting challenge for the future.

Revolutionizing Patient and Physician Experiences through Digital First Strategies - In this week's episode of Life Science Success, we dive into the intersection of digital innovation and healthcare commercialization with leaders from Indegene, a company revolutionizing patient and physician experiences through digital-first strategies. We'll explore the journeys of Nancy Phelan, a biopharma commercial strategy expert; Jeff Rothstein, a marketing visionary who has significantly expanded Indegene's brand and capabilities; and Kevin Patterson, a strategic thinker in medical solutions, as they share insights on driving healthcare forward in today's complex landscape.

 

Key Takeaways:

1. Interdisciplinary Innovation: The convergence of diverse backgrounds and expertise is driving innovation in healthcare, emphasizing the importance of storytelling and engagement in healthcare marketing.
2. Digital Transformation: The shift towards digital and data-driven strategies is revolutionizing patient and physician experiences, making healthcare more personalized and accessible.
3. AI's Growing Influence: Artificial intelligence is poised to transform healthcare delivery and treatment, with current applications representing just the tip of the iceberg.
4. Navigating Market Access Challenges: Successfully bringing new treatments to market requires overcoming regulatory and accessibility hurdles, highlighting the need for strategic market access planning.
5. Optimism for the Future: Despite challenges, there's a strong sense of optimism about the future of healthcare, driven by technological advancements and a commitment to improving patient care.

This week on Life Science Success, we're excited to welcome Donald Zinn, a seasoned professional with nearly three decades of experience in the biotech, pharmaceutical, and medical device industries. Beyond his executive roles, Don contributes to the National Institutes of Health (NIH) as a Commercialization Grant Reviewer and has played a pivotal role at Crossject, leading their needle-free auto-injector platform to global success since the onset of COVID.

 

• Donald Zinn's Background and Experience: Donald Zinn, the Vice President of US Business at Crossject, has nearly 30 years of experience in the life sciences industry. He started his career with an undergraduate degree from UMBC and went on to innovate in the field by inventing dry process microarray during his time at the Uniform Services University. His journey included roles such as lab manager at Georgetown University's HIV Center, and leadership positions in companies focused on oncology, infectious diseases, and more.

• Crossject's Needle-Free Auto Injector: Zinn is part of the Crossject team, working on a needle-free auto injector, which he finds to be an exciting and innovative technology. This device is designed to deliver medications quickly and without the need for needles, addressing needle phobia and improving patient compliance.

• Demonstration of the Injector's Ease of Use: During the podcast, a demonstration was discussed showing how the injector works, including its ability to administer medication through clothing. This feature is particularly advantageous in emergency situations where speed and ease of use are critical.

• Focus on Partnerships and Market Expansion: Zinn emphasizes the importance of finding the right partners worldwide to distribute Crossject's needle-free injector. The company aims to select partners based on their expertise and market presence to ensure the technology is accessible to a broad audience.

• Future Prospects and Industry Impact: The conversation highlighted the potential of Crossject's technology to revolutionize drug delivery, especially for emergency medications like epinephrine. The ease of use, coupled with the effectiveness of the needle-free injector, presents a significant advancement in patient care and medication administration.

In this episode of Life Science Success, my guest is Dr. Kate Broderick. Dr. Broderick has more than 15 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery fields. She also actively works with teams at TriLink BioTechnologies, a Maravai company, to advance its global reagents and manufacturing services.

 

• Dr. Kate Broderick's Background: Originally from Scotland, Kate Broderick's academic journey began with using animals as models for human diseases. Her passion lies at the intersection of science and clinical application, leading her to focus on DNA therapeutics and drug delivery fields in the United States, particularly after her postdoctoral work at UCSD.
• Focus on DNA and RNA Technologies: Dr. Broderick is motivated by the fundamental roles of DNA and RNA in medicine. She discusses the potential of these molecules to revolutionize treatments, vaccines, and therapies, foreseeing a future where new medical solutions are developed using these technologies.
• Career Development and Innovation: Throughout her career, Dr. Broderick has embraced various roles beyond her scientific training, including clinical development and finance, which have enriched her understanding of product development and corporate strategy within biotech startups.
• Role as Chief Innovation Officer at Maravai: In her current role, Dr. Broderick emphasizes the importance of innovation in staying ahead in the fast-paced field of life sciences. She discusses fostering collaborative environments for scientists, integrating client needs into R&D, and focusing on structured innovation to drive the company's mission forward.
• Concerns and Future Outlook: Dr. Broderick expresses concerns about vaccine hesitancy and misinformation, emphasizing the need for better communication in the scientific community. She is excited about the future of nucleic acid medicines, predicting significant advancements in treating various diseases and developing new vaccines within the next decade.

     

In this episode of Life Science Success, my guest is Dr. Thomas Rademacher. Professor Rademacher, MD, PhD, co-founded Emergex and has served as CEO since the Company’s formation. He is an Emeritus Professor of Molecular Medicine at University College London (UCL) and a serial entrepreneur.

 

• Dr. Thomas Rademacher, MD, PhD, is the co-founder and CEO of Emergex, with a background as an Emeritus Professor of Molecular Medicine at the University College of London and a serial entrepreneur. His career has oscillated between academic and entrepreneurial roles, adhering to the philosophy of not staying in the same job for more than ten years.
• Rademacher's academic foundation in hardcore biochemistry was established during his PhD at the University of Wisconsin Madison. This rigorous training in biochemistry has been a cornerstone throughout his career, enabling him to navigate and innovate in the complex field of molecular medicine.
• His work has significantly contributed to the field of monoclonal antibodies, starting with foundational research at Oxford and involving the use of Chinese hamster ovary (CHO) cells. This work was pivotal for the development of recombinant proteins and monoclonal antibodies, leading to advancements in medicine.
• Rademacher has been involved in groundbreaking research and entrepreneurial ventures, including the Glycobiology Institute, which attracted interest from major corporations like Monsanto. His work has led to significant scientific advancements and the formation of companies that have had substantial impacts on the medical and biotechnological landscapes.
• He is currently focused on challenges in vaccinology and immunology, particularly in developing vaccines that activate the cellular immune response to fight viral infections effectively. Rademacher's innovative approach involves utilizing quantum-confined gold clusters and micro-needle technology to enhance vaccine delivery and efficacy.

Ronan O’Hagan, President & CEO, Bectas Therapeutics Inc.  Rónán is a founder and the President and Chief Executive Officer for Bectas Therapeutics Inc. He has over 20 years of experience in oncology R&D including bringing over 20 molecules through IND and into clinical development and helping to guide 4 drugs through clinical development to FDA approval.

 

• Ronan O'Hagan is the President and CEO of Bectas Therapeutics, a cancer drug discovery and development company with over 20 years of experience in oncology R&D. He has been instrumental in advancing over 20 molecules through IND (Investigational New Drug) to clinical development and guiding four drugs through clinical trials to FDA approval.
• His approach at Bectas Therapeutics focuses on utilizing insights from human patients' immune responses to develop precision therapies, aiming to find the right drug for the right patient. This approach stems from his belief that understanding cancer's complexity requires a deep understanding of patients themselves.
• O'Hagan's career includes significant roles in various organizations: Chief Scientific Officer at Apricity Health and Exilio Therapeutics, leader of the Oncology Discovery team at Merck Research Labs, and involvement in a biotech startup originating from Dana Farber Cancer Institute.
• He emphasizes the importance of values like focusing on patients, people, and proof of concept in drug development. He believes in balancing innovation with discipline and highlights the need for collaborative but strong leadership in the pharmaceutical industry.
• O'Hagan discusses the challenges and triumphs of drug development, stressing the importance of speed in bringing therapies to patients and the need for alignment around core values within a team. He also underlines the role of precision in enhancing the effectiveness of immune therapies and the necessity of inclusive research to benefit diverse patient populations.

In this episode of Life Science Success, my guest is Matt Hill, Ph.D.  Matt is founder and CEO of Elegen Corp., a privately-held company based in the San Francisco Bay Area committed to revolutionizing synthetic biology workflows with innovative DNA writing technology.

 

1. Background and Experience: Matt Hill has a Ph.D. in genetics from Stanford University and was initially attracted to the Bay Area for its vibrant startup ecosystem. After completing his Ph.D., he joined Nera, a leading molecular diagnostics company, where he contributed to product development and new capabilities, particularly in massively multiplex PCR technology.

2. Journey to Founding Elegen: Hill's experience at Nera, especially in DNA synthesis and production challenges, led him to identify DNA production as a critical bottleneck in life sciences. His interest in solving complex problems and connecting technology areas motivated him to found Elegen to address these challenges in DNA synthesis and production.

3. Elegen's Impact and Infinia DNA: Elegen's product, Infinia DNA, aims to streamline workflows in life sciences, providing researchers with faster, more accurate DNA synthesis. This technology impacts various fields, including therapeutics and synthetic biology, by enabling quicker and more efficient product development cycles.

4. Leadership and Vision: As a leader, Hill emphasizes inspiration, encouragement, and problem-solving. He discusses the importance of Elegen's technology in advancing fields like personalized therapeutics and its potential in addressing major health challenges. Hill also highlights the need for more investment in foundational research and development to foster scientific progress.

In this episode of Life Science Success, Ross Jackson, the guy who wrote two books about patient recruitment, is returning to tell us about his new patient recruitment book. Ross is a specialist in patient recruitment for clinical trials, having helped deliver many thousands of patient registrations for clients in the UK, Europe, and the US.

 

The key highlights from the interview:

• Ross Jackson is a specialist in patient recruitment for clinical trials with experience in the UK, Europe, and the US. He has authored two books on the subject.

• His career journey began in digital marketing, where he initially recruited patients for a doctor's new treatment. Over time, he shifted his focus to healthcare and clinical trial recruitment.

• Patient recruitment faces challenges related to awareness and access. Many people are unaware of clinical trials, and misconceptions like being seen as "guinea pigs" persist. Lack of understanding about the importance of clinical research compounds the issue.

• Ross Jackson's first book focused on using Facebook ads for patient recruitment. It aimed to make it easier for research sites and others to access potential trial participants effectively.

• His new book takes a unique approach, featuring a fictional character named Josh Black, a puzzle solver who tackles patient recruitment challenges. The book explores various aspects of patient recruitment and aims to make the topic more accessible and engaging.

• Ross emphasizes the need for collaboration within the industry and the potential impact of AI, particularly natural language processing, in improving patient recruitment processes.

• He also mentions his excitement about attending a conference and watching his first Super Bowl in Orlando, highlighting his interest in sports and the upcoming event.

• The interview concludes with gratitude for sharing information about his new book and the hope that it will benefit those interested in patient recruitment. The book is available on Amazon.

In this episode of Life Science Success, my guest is Dr. Lishan Aklog.  Dr. Aklog is the CEO of Lucid Diagnostics he also co-founded and has served as Chairman and Chief Executive Officer of Lucid’s parent company, PAVmed Inc (Nasdaq: PAVM) since its inception in 2014, and as Executive Chairman of PAVmed’s other major subsidiary, digital health company Veris Health Inc., since its inception.

 

1. Dr. Lishan Aklog's Background: Dr. Aklog, CEO of Lucid Diagnostics and executive chairman of PAVmed’s subsidiary Varys Health, was a cardiothoracic surgeon with a strong interest in technological innovation in medicine. He has an extensive background in academic cardiac surgery and was actively involved in medical device innovation.

2. Transition to Entrepreneurship: Transitioning from a successful career in cardiac surgery, Dr. Aklog co-founded Lucid Diagnostics and PAVmed. He ventured into medical device entrepreneurship, focusing on developing and commercializing innovative technologies. He was instrumental in creating and selling medical devices, notably a device for non-surgically removing clots.

3. Lucid Diagnostics and Focus on Cancer Detection: Under Dr. Aklog’s leadership, Lucid Diagnostics specializes in early cancer detection, particularly esophageal cancer. Dr. Aklog emphasizes the importance of pre-cancer detection and prevention, highlighting the challenges in raising awareness and adherence to screening guidelines.

4. Challenges and Achievements: A significant challenge in Dr. Aklog's journey has been raising capital to bring innovative technologies to market. Despite these challenges, Lucid Diagnostics has made substantial progress, especially in gaining payer coverage and launching large-scale screening programs.

5. Leadership and Vision: Dr. Aklog's leadership philosophy centers on building a culture of success, teamwork, and innovation. He stresses the importance of surrounding oneself with talented individuals and working cohesively towards a shared mission, with a particular focus on impacting patient lives through advanced medical technologies.

In this episode of Life Science Success my guest is Roee Hevrony. Roee is the CFO of ImmunoBrain Checkpoint. Prior to joining IBC in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch.

 

• The podcast features an interview with Roee Hevrony, the CFO of ImmunoBrain Checkpoint.
• Roee Hevrony discusses his background, which includes growing up in Israel and working in investment banking before joining ImmunoBrain.
• ImmunoBrain is focused on a novel approach to treating neurodegenerative diseases by targeting the immune system rather than the brain itself.
• The company has been conducting research for nine years, expanding from basic research to clinical studies, with a unique therapy approach.
• Roee Hevrony emphasizes the importance of long-term vision and patience in the pharmaceutical industry, especially in the field of neurodegeneration.

In this episode of Life Science Success, Don interviews Dr. Geoffrey Stephens, the CEO of AICella, who brings over 20 years of experience in biotechnology. Dr. Stephens delves into his impressive background in immunology and CAR T cell therapies, sharing invaluable insights into the impact of artificial intelligence on the efficiency and affordability of manufacturing cell therapies.   This discussion, which D3 Digital Media Marketing is sponsoring, covers Dr. Stephens' contribution to the FDA's approval of Fasenra for asthma, the difficulties and myths surrounding AI in healthcare, and the future of personalized medicine. Tune in to learn how AICella is poised to revolutionize the field of cell therapy with innovative AI-driven solutions.     00:00 Introduction to Life Science Success Podcast 00:40 Sponsor Message: D3 Digital Media Marketing 01:18 Meet Dr. Jeffrey Stevens, CEO of AICella 01:47 Dr. Stevens' Journey in Biotechnology 03:56 The Impact of CAR T Cell Therapies 06:29 Challenges and Innovations in Cell Therapy 18:47 AI's Role in Revolutionizing Cell Therapy 31:11 Future of Personalized Medicine and Cell Therapies 34:07 Collaborations and Data Sharing in Life Sciences 40:30 Leadership Insights and Inspirations 49:44 Closing Remarks and Podcast Information  

In this episode of Life Science Success, my guest is Tom Hartman.  Tom is the President and CEO of the International Society of Pharmaceutical Engineering (ISPE), Tom leads a global network of 20,000+ professionals spanning the complete pharmaceutical lifecycle.

 

In this edition of Life Science Success, Don Davis interviews Tom Hartman, the president and CEO of the International Society of Pharmaceutical Engineering (ISPE). They discuss Hartman's career journey and the role of the ISPE in the life sciences industry. Hartman discusses the critical role of the society's volunteer network and emphasizes the importance of speed, quality, and solid decision-making in the industry. Concerns about industry shortages, workforce challenges, and readiness for future potential pandemics also arise. Hartman highlights several exciting incursions, such as the 'Facility of the Year Award' and ISPE's workforce of the future initiative. The interview sheds light on the ISPE's strategic goals and the overall current industry landscape and trends.

In this episode of the Life Science Success Podcast my guests are James Foster, CEO of Virax Labs and Nigel McCracken COO of Virax Labs.  Virax Labs is a global biotechnology company specializing in the development of innovative diagnostic solutions. They focus on T-cell testing and immune profiling, with a novel portfolio of FluoroSpot T-cell diagnostics aimed at indications associated with chronic inflammation and T-cell exhaustion.

 

• Podcast Overview: The first "Life Science Success" podcast episode in 2024 features James Foster, CEO, and Nigel McCracken, COO, of Virax Biolabs. 

• James Foster's Background: James Foster, CEO of Virax Biolabs, co-founded the company about 10 years ago. Initially starting in finance, he shifted to biotech and diagnostics due to his entrepreneurial interests, particularly influenced by the 2008 financial crisis. His goal is to develop comprehensive immune profiling in-vitro diagnostics (IVDs), focusing on early diagnosis of post-viral syndromes, chronic inflammation, and T-cell exhaustion.

• Virax Biolabs' Mission and Technology: Virax is dedicated to creating innovative diagnostic solutions, particularly their T-cell testing platform. This platform aims to address significant health issues like long COVID, affecting millions in the US and Europe. Foster emphasizes the importance of early detection in disease progression and the role of the immune system in combating pathogens.

• Nigel McCracken's Role and Insights: As COO, Nigel McCracken plays a crucial role in scaling Virax from a small team to a larger organization. He discusses the importance of strategic focus, effective decision-making, and the development of companion diagnostics, which are essential for personalized medicine, especially in oncology.

• Future Outlook and Challenges: Both Foster and McCracken highlight the challenges in biotech, including the need for innovation, execution, and efficient leadership. They foresee an increasing burden on healthcare systems due to post-viral syndromes and chronic conditions. The podcast also touches on the potential of venture capital in fostering new ideas and innovations in the biotech sector.

 

In this episode of Life Science Success, we are welcoming back Dr. AJ Mellott. Dr. Mellott is the CEO and Co-Founder, Ronawk manufacturer of customized tissue-mimetic technology that is advancing science.

 

1. Dr. AJ Mellott is the CEO and co-founder of Ronawk, a company that specializes in creating hydrogel substrates that mimic various tissues in the human or animal body.
2. Ronawk's tissue mimetic technology is used in cell culture to produce high-quality, active cells that are valuable for medical and diagnostic applications.
3. The company has recently expanded and moved to Overland Park, Kansas, and has experienced significant growth in its team and production practices.
4. Ronawk's technology has facilitated collaborations between researchers in different fields and has lowered barriers to experimentation and innovation in the life sciences.
5. Dr. Mellott is excited about the potential of AI and machine learning to streamline research processes and the personalized screening of therapies for patients, ultimately improving healthcare outcomes.

In this episode of Life Science Success, my guest is Dr Paul Song. Dr. Song has served as Chief Executive Officer and Vice Chairman of NKGen since December 2022.

 

1. Dr. Paul Song, CEO and Vice Chairman of NKGen since December 2022, shares his background as a radiation oncologist and his journey into biotech.
2. Dr. Song talks about the importance of natural killer cells in the body's defense against diseases and their potential in treating conditions like Alzheimer's.
3. NKGen's phase one trial showed promising results, with 90% of patients either stabilizing or improving in Alzheimer's treatment.
4. NKGen is also exploring the use of natural killer cells in combination with other cancer therapies to enhance their effectiveness while minimizing side effects.